The genuinely unsettled questions in clinical cardiology, ranked by debate-worthiness. Scanned continuously from the major journals, FDA actions, new guidelines, and the conversation among cardiologists on X.
Last scanned Jun 24, 2026, 8:38 AM UTC
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.3 · 40%
How much practice changes9.0 · 30%
How much is genuinely new9.4 · 20%
Clinician attention8.7 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.9 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 94%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (3 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (9 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Aug 2024).
On the boardhow long the question has been live on Synapse (13 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
01Field-wide debate
Continuing beta-blockers long-term after uncomplicated MI
Get this wrong and millions of stable post-MI patients either swallow a daily pill for nothing or lose real arrhythmia and remodeling protection.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.8 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.8 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.0 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.8 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.3 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.5 · 40%
How much practice changes
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.8 · 40%
How much practice changes
Debates are surfaced by a continuous scan of the cardiology literature and the conversation among clinicians. The heat score (0-10) reflects how live and consequential the disagreement is right now and drives the ranking; it becomes the measured expert split as cardiologists weigh in. Quotes and engagement counts are scan-reported and link to their primary source.
9sources
›Open the debateClose
The debate
In revascularized post-MI patients with preserved EF on modern guideline therapy, should clinicians routinely stop the beta-blocker or continue it indefinitely?
Stop the beta-blocker
Modern trials in patients with preserved EF show no survival or event benefit, so continuing only adds side effects, fatigue, and pill burden with nothing to gain.
Keep it going
Beta-blockers still guard against arrhythmias and adverse remodeling, and the newer trials may miss harder, longer-term events the older data captured.
Expert commentary
Stop the beta-blocker
“Beta-blockers have long been a foundational treatment after acute MI; however, supporting evidence is derived from trials that predate modern standards of care − before the time of routine reperfusion, invasive management, potent antiplatelet therapies and statins. Re-examining t”
“Based on the REDUCE-AMI trial results, I would recommend that routine beta-blockers for patients like those included in that trial (revascularized 1- or 2-vessel disease and LVEF ≥50%) is no longer necessary.”
“Differences between the groups with respect to hospitalisation for cardiovascular reasons and the negative effect on blood pressure levels, together with the absence of quality-of-life improvement do not support interruption of a chronic beta-blocker treatment in post-MI patients”
Named experts we found publicly on record — a sample, not a representative poll of the field.
Who: Post-MI patients with LVEF >40%·9 sources
On the board:since Jun 12, 2026 (13 days)— time live on Synapse
Patients affected:Millions of patients· preserved EF after common heart attack
›The evidence
What we know
✓Beta-blockers clearly help post-MI patients with reduced EF.
✓The original survival evidence comes from a pre-reperfusion, pre-modern-GDMT era.
✓Recent trials in preserved-EF patients show no clear reduction in death or major events.
✓Many post-MI patients today are revascularized and on full guideline therapy.
What's still unknown
?Whether stopping raises long-term arrhythmia or recurrent-event risk beyond the trial windows.
?Which preserved-EF subgroups, if any, still benefit.
?Whether the EF >40% versus EF ≥50% cutoff changes the answer.
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
8.5
· 30%
How much is genuinely new9.7 · 20%
Clinician attention8.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.7 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (3 vs 2 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (7 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Sep 2024).
On the boardhow long the question has been live on Synapse (13 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
02Field-wide debate
Asundexian for secondary prevention after noncardioembolic stroke
Get this right and you add a bleeding-sparing pill on top of antiplatelets for millions of stroke survivors; get it wrong and you layer cost and uncertainty onto a population that already does okay on aspirin alone.
›Open the debateClose
The debate
For a 70-year-old with a recent atherosclerotic noncardioembolic stroke finishing short-course DAPT, would you add asundexian to single antiplatelet therapy now on the strength of OCEANIC-STROKE alone — or does the OCEANIC-AF failure (which suggested the chosen dose may be subtherapeutic for thrombin-driven events) mean you require a confirmatory trial or dose-ranging clarity before layering a factor XIa inhibitor onto antiplatelet therapy outside a study?
Adopt for eligible patients
A single positive trial shows fewer recurrent strokes with no extra major bleeding — a clean win in a population where we badly need better options beyond antiplatelets.
Wait before adopting
One trial in a selected population, with unknown long-term safety, no head-to-head against established agents, and a failed sibling trial in AF, isn't enough to change practice or guidelines yet.
Expert commentary
Adopt for eligible patients
“The curves diverged early, and that divergence continued throughout the treatment period.”
Weighted (40 / 30 / 20 / 10) into the 8.6 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 94%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (4 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (7 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Mar 2026).
On the boardhow long the question has been live on Synapse (13 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
03Field-wide debate
Role of CAC scoring in intermediate-risk patients per 2026 ACC/AHA dyslipidemia guideline
Get the thresholds wrong and millions of low-risk adults start lifelong statins they may never have needed — or get them right and you finally catch the patients who slip through current risk scores.
›Open the debateClose
The debate
In borderline/intermediate-risk primary prevention adults, should PREVENT-driven lower thresholds and universal Lp(a) testing trigger statin therapy now, or should CAC scoring be required to confirm risk before treating?
Appropriately intensifies prevention
Lower thresholds plus once-in-a-lifetime Lp(a) testing catch high-risk people that older risk equations miss, and starting statins earlier in the right patients prevents events decades down the line.
Will over-treat the well
Many of these new Class I recommendations rest on modeling and observational data rather than randomized outcome trials, so lowering the bar risks medicating large numbers of people who would never have had an event.
Expert commentary
Appropriately intensifies prevention
“The guideline supports Lp(a) measurement at least once in all adults to refine ASCVD risk assessment.”
Robert S. Blumenthal · Guideline writing committee chair · JACC ↗
7.5
· 30%
How much is genuinely new9.4 · 20%
Clinician attention8.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.4 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (5 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (8 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Aug 2025).
On the boardhow long the question has been live on Synapse (13 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
04Field-wide debate
Place of baxdrostat in resistant/uncontrolled hypertension
Decide this wrong and patients with stubborn high blood pressure either miss a genuinely better drug or get an expensive new pill bolted on before we know it prevents a single heart attack or stroke.
›Open the debateClose
The debate
In a patient with resistant hypertension on a maximally tolerated three-drug regimen (ACEi/ARB + CCB + thiazide) and eGFR >45, do you add baxdrostat — a targeted aldosterone synthase inhibitor with BaxHTN's ~9 mmHg SBP reduction but no outcomes data — or stick with spironolactone, which has PATHWAY-2 evidence, decades of safety data, and generic pricing, reserving baxdrostat only for those who fail or can't tolerate the MRA?
Adopt now
A first-in-class aldosterone synthase blocker delivers a meaningful blood pressure drop and may spare patients the hormonal side effects that wreck adherence to spironolactone.
Prove it first
Until we see hard outcomes and a head-to-head against cheap spironolactone, a ~9 mmHg drop and a hyperkalemia signal don't justify displacing a proven, low-cost therapy.
Expert commentary
Adopt now
“Full context and implications will depend on comparison of efficacy and tolerability of spironolactone (existing cheap therapy). It is always tricky to compare blood pressure (BP) reductions in different trials, but the efficacy of baxdrostat here looks similar to that of spirono”
Morris J Brown ·
8.0
· 30%
How much is genuinely new8.2 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.2 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (0 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (7 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Jun 2020).
On the boardhow long the question has been live on Synapse (2 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
05Field-wide debate
Watchman FLX as first-line vs NOACs in eligible AF patients?
Get this wrong and a generation of stroke-eligible AF patients trades a daily pill they could safely take for a permanent implant that may leave them more prone to stroke.
›Open the debateClose
The debate
In AF patients fully eligible for long-term anticoagulation, should left atrial appendage closure be offered as a first-line alternative to NOACs given a noninferior composite but a higher ischemic stroke signal?
Offer the device early
Trials met noninferiority for the hard composite while cutting serious nonprocedural bleeding, so patients who hate or fear lifelong anticoagulation finally have a real alternative without waiting to fail pills first.
Keep pills first-line
The numerically higher ischemic stroke signal, soft composite endpoints, and industry funding mean we can't yet call a one-time implant equal to a proven drug we can stop if something goes wrong.
Expert commentary
Keep pills first-line
“I’m not convinced that these devices should be considered an equal substitute for NOACs.”
Weighted (40 / 30 / 20 / 10) into the 7.7 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 100%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Sources — the evidence behind it
How many distinct sources we linked for this debate (9 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Mar 2025).
On the boardhow long the question has been live on Synapse (2 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
06Field-wide debate
IVUS guidance routine in complex PCI: still mandatory after neutral trials?
Make imaging mandatory and every complex PCI gets slower and costlier; make it optional and some patients lose the stent optimization that prevents repeat procedures.
›Open the debateClose
The debate
In patients undergoing complex PCI, should intravascular imaging be mandated routinely or reserved for the highest-risk lesions, given two neutral and one positive recent trial?
Image every complex case
The weight of prior evidence shows intravascular imaging improves stent sizing and expansion, and the neutral trials likely reflect underpowering or skilled operators, not a real absence of benefit.
Reserve for highest-risk
When recent trials can't consistently show benefit, routine mandates add time, cost, and contrast without proven payoff, so imaging belongs where lesion complexity truly demands it.
Expert commentary
Undecided
“We have yet to fully establish how to leverage the unique information provided by intravascular imaging.”
Weighted (40 / 30 / 20 / 10) into the 8.0 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (3 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (6 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Jan 2024).
On the boardhow long the question has been live on Synapse (13 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
07Field-wide debate
Integration of anti-inflammatory therapies (colchicine, IL-6 inhibitors) for residual CV risk
Decide this wrong and millions of stable heart disease patients get a daily anti-inflammatory pill — and its bleeding, GI, and cost burden — for a benefit that may not exist beyond good LDL control.
›Open the debateClose
The debate
In ASCVD patients already at LDL goal, should anti-inflammatory therapy be offered broadly, or restricted to those with elevated CRP?
Treat the inflammation
Even on perfect lipid therapy, residual inflammatory risk drives events, and we now have an approved, cheap pill plus a strong trial precedent showing cutting inflammation cuts events.
Reserve and prove first
Recent colchicine trials have been mixed, the benefit beyond LDL is unproven for most patients, and adding another drug brings real bleeding, GI, and polypharmacy costs.
Expert commentary
Treat the inflammation
“After aspirin and statins, low-dose colchicine may well be the third most cost-effective treatment developed for chronic stable atherosclerosis.”
Weighted (40 / 30 / 20 / 10) into the 7.7 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 97%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (1 vs 0 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (8 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Jan 2022).
On the boardhow long the question has been live on Synapse (2 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
08Field-wide debate
TAVR or SAVR for lifetime management in young low-risk aortic stenosis patients?
Pick wrong for a 55-year-old and you either lock them into a TAVR-in-TAVR future nobody has decades of data on, or you put them through open surgery they may not have needed.
›Open the debateClose
The debate
For patients under 65 with severe aortic stenosis and current durability data, should the first valve be surgical to protect lifetime options, or transcatheter with a plan to reintervene?
Surgery first
A young patient has decades ahead, and a durable surgical valve preserves the cleanest options for the inevitable reinterventions that lie down the road.
TAVR first
Outcomes match surgery out to several years with faster recovery, and the patient can start with the less invasive option and plan to layer valves later.
Expert commentary
Surgery first
“The SAVR/TAVR decision is a lifetime strategy, not a single episode of care.”
Weighted (40 / 30 / 20 / 10) into the 7.6 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (4 vs 3 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (8 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Nov 2023).
On the boardhow long the question has been live on Synapse (2 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
09Field-wide debate
Does CKM staging change care, or just relabel sick patients?
CKM syndrome staging: practical tool or added complexity?
Get this wrong and busy clinicians spend visits sorting patients into stages that don't change a single prescription — or miss a real chance to treat heart, kidney and metabolic disease as one problem before it advances.
›Open the debateClose
The debate
For patients with overlapping cardiac, kidney and metabolic disease, does assigning a CKM stage change management beyond existing guideline-directed therapy, or does it mainly relabel multimorbidity?
Practical tool
Staging plus early risk estimation catches overlapping heart, kidney and metabolic disease sooner and pushes coordinated care before patients progress to overt organ damage.
Added complexity
The stages lump together very different disease causes and don't tell you to do anything beyond the guideline-directed therapy you'd already give — so it's relabeling, not management.
Expert commentary
Practical tool
“The statement reviews and synthesizes the evidence supporting the new Guideline's recommendations for the use of predicted risk to inform staging, strategies for efficient detection of subclinical cardiovascular disease in appropriate patients, and decision-making for CKM therapi”
Weighted (40 / 30 / 20 / 10) into the 7.2 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (2 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (9 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Sep 2024).
On the boardhow long the question has been live on Synapse (2 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
10Field-wide debate
Add finerenone on top of SGLT2 inhibitors in HFpEF?
Finerenone in HFpEF with CKD and diabetes: add to SGLT2i?
Layer two pricey drugs on every diabetic HFpEF patient with kidney disease and you may cut more events — or just add cost and potassium scares for little extra gain.
›Open the debateClose
The debate
In HFpEF patients with type 2 diabetes and CKD already on an SGLT2 inhibitor, should finerenone be added routinely given only indirect and real-world evidence of additive benefit?
Stack both drugs
Finerenone and SGLT2 inhibitors hit different pathways, real-world signals show fewer deaths and admissions when combined, and SGLT2 inhibitors may even blunt the potassium rise.
SGLT2i is enough
The added benefit over an SGLT2 inhibitor alone in HFpEF is unproven, and finerenone still carries hyperkalemia risk and cost that aren't justified without dedicated trial data.
Expert commentary
Stack both drugs
“In patients with HFpEF and diabetic CKD stages 3-5, addition of finerenone to SGLT2 inhibitor therapy was associated with significant reductions in all-cause mortality and hospitalizations, without increased hyperkalemia risk despite advanced renal dysfunction.”
Weighted (40 / 30 / 20 / 10) into the 6.9 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (3 vs 0 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (9 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Sep 2017).
On the boardhow long the question has been live on Synapse (13 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
11Field-wide debate
Precision phenotyping and mechanism-targeted therapy in MINOCA
Resolve this and every MINOCA patient either gets an invasive workup that finally names their disease — or keeps getting one-size-fits-all pills, some of which may make the vasospasm subset worse.
›Open the debateClose
The debate
In MINOCA patients with only symptom-improvement evidence and no outcome RCT, should a structured invasive phenotyping workup become the default, or stay reserved until outcome data and access catch up?
Phenotype everyone
We already have OCT, CMR, and provocation testing that pin down the mechanism in most patients, and treating blind risks giving harmful beta-blockers to the spasm subset while leaving real causes untreated.
Treat empirically
Without outcome trials showing phenotyping saves lives, routinely subjecting every MINOCA patient to invasive provocation and CMR is costly, often unavailable, and not yet justified beyond symptom relief.
Expert commentary
Phenotype everyone
“a comprehensive evaluation and a multimodal assessment aimed at uncovering the aetiology of MINOCA should be pursued in order to implement a tailored therapeutic approach targeted to the specific underlying cause.”
Weighted (40 / 30 / 20 / 10) into the 7.0 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 94%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Sources — the evidence behind it
How many distinct sources we linked for this debate (7 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: contested vs. on the board
These measure different things, so the card keeps them apart:
Contestedhow long the real-world debate has existed, from the earliest dated source we found (Apr 2023).
On the boardhow long the question has been live on Synapse (2 days).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
12Field-wide debate
Myosin inhibitors for obstructive HCM: first-line or after beta-blockers?
Pick wrong and patients either swallow a costly drug needing constant echo monitoring when cheap beta-blockers would do, or keep getting septal procedures we could have avoided.
›Open the debateClose
The debate
In symptomatic obstructive HCM, should myosin inhibitors be used as first-line therapy or reserved until beta-blockers or calcium channel blockers fail, given no mature head-to-head data?
Cheap drugs first
Beta-blockers and verapamil are inexpensive, decades-proven, and safe, so a pricey myosin inhibitor with mandatory echo surveillance should wait until they fail.
Inhibitors earlier
Myosin inhibitors target the actual disease mechanism, relieve obstruction directly, and can spare patients an invasive septal reduction the older drugs never prevent.
Expert commentary
Undecided
“Currently, myosin inhibitor therapy is recommended as a second-line treatment for patients with persistent symptoms on beta-blockers. But here we show that aficamten – as monotherapy and as first-line therapy – demonstrated greater improvements in exercise capacity and symptoms t”
Pablo Garcia-Pavia · Principal Investigator · ESC ↗
?
Real-world outcomes of structured deprescribing versus continuation.
“These findings support the potential of asundexian as a broadly applicable therapeutic option for patients with non-cardioembolic ischemic stroke or high-risk TIA who meet trial eligibility criteria.”
“very groundbreaking for us clinicians who take care of stroke patients because it expands our armamentarium of secondary stroke prevention tools that we can offer our patients as an adjunctive therapy without incurring the competing risk of hemorrhage.”
“Asundexian appears to be a very promising option for secondary prevention after noncardioembolic ischemic stroke or TIA. However, further studies of factor XI inhibitors with longer follow-up (e.g., 5 or 10 years) are necessary to determine whether the net clinical benefit will b”
“It’s exciting, because now we’re looking at a completely new class of blood pressure medication.”
Jenifer Brown · Brigham and Women’s Hospital · HCPLive ↗
Prove it first
“This is a potential game changer for patients because at the present time . . . despite the best efforts of clinicians and the drugs they have available, at least 50% of patients, even in the most developed healthcare systems, don’t have their blood pressure controlled.”
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
“If positive, the results of our trial will create a new paradigm of combining mechanical and medical strategies to prevent stroke among patients with AF who are at higher risk of stroke.”
Jeff Healey · Cardiologist/Electrophysiologist · PHRI ↗
“LAA occlusion remained noninferior to DOAC therapy in terms of the primary composite endpoint.”
“Obviously, it is related to years and years of experience to reach a certain level of confidence where you can have the choice of deciding whether it’s mandatory or it’s just a plus.”
Luca Testa · Head of Coronary Revascularization Unit · Medscape ↗
“Once we are very skilled in PCI, probably we can use IVUS just in a selected proportion of our patients.”
“The bottom line is that imaging is extremely valuable in evolving one’s PCI practice, but the incremental benefit of imaging becomes harder to show for great operators.”
Ajay J. Kirtane · Director of Columbia Interventional Cardiovascular Care · Medscape ↗
“These results extend the strong recommendations from recent U.S. and European societal guidelines that intravascular imaging with either optical coherence tomography (OCT) or intravascular ultrasound (IVUS) should be routinely used during complex coronary stent procedures.”
Gregg W. Stone · Interventional cardiologist · Mount Sinai ↗
“IVUS significantly reduces target vessel failure in complex coronary bifurcations treated with DK crush.”
“In patients with complex coronary lesions undergoing PCI with DES, both OCT-guided PCI and IVUS-guided PCI are more effective at reducing target lesion failure than angiography-guided PCI.”
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
“If you think their other risk factors are well controlled but they are still having recurrent events, then we can consider colchicine as a way of reducing their residual risk which is likely being caused by inflammation.”
Michael J. Blaha · Preventive cardiologist · Medscape ↗
“Colchicine 0.5 mg is the first FDA-approved anti-inflammatory therapy indicated for reducing cardiovascular events among adults who have established ASCVD or are at risk of developing it.”
“However, trials in patients with acute coronary syndrome (ACS) yielded conflicting results, and two trials in patients with ischemic stroke did not show a benefit.”
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
“This is the first study to demonstrate that newer generation TAVR valves not only appear durable when compared to surgery but may potentially offer slightly better outcomes in specific parameters such as all-cause mortality or disabling stroke.”
“Finally, in the lifetime management of aortic stenosis, SAVR is seriously considered in patients’ younger years to match procedural risk and advancing age appropriately.”
“When the aortic valve anatomy is favorable for TAVR and transfemoral access is possible, TAVR will result in clinical outcomes comparable to those of SAVR. In contrast, when patients have unfavorable anatomy in the TAVR implantation zone or poor femoral access, SAVR is the treatm”
“Although the 5-year result of this trial provides compelling evidence with no significant negative signal against TAVR in terms of the main clinical outcomes and valve performance, our journey to understanding the lifetime management of aortic stenosis is still at its dawn.”
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
“The staging system, plus risk estimation with the PREVENT equations, can help us better identify risk earlier, prevent progression along the spectrum, which is really important for cardiovascular outcomes and for mortality, and promote the concept of regression.”
“CKM Syndrome Staging: CKM syndrome staging is recommended for youths and adults to prevent CKM stage progression, to tailor therapy to absolute risk, to reduce cardiovascular events and loss of kidney function across the life course, and to promote CKM stage regression through li”
“Cardiometabolic disease is a systemic condition, encompassing a continuum of different conditions driven by common underlying pathophysiological mechanisms, including adiposity, insulin resistance and chronic inflammation.”
“In light of these considerations, the current staging of CKM proposed by the AHA should be reconsidered. While the AHA model categorized CKM syndrome into five distinct stages (stages 0–4), each of these stages has been analyzed and redefined to incorporate novel insights and per”
“New AHA Cardiovascular-Kidney-Metabolic (CKM) Staging Solves All Our Staging Problems and Should Be Applied Universally… Not really. The staging system Ignores etiologies of different kidney and CV diseases. Is not simple to use for clinicians or researchers yet.”
“We’ve seen the primary data. The primary data showed that it was safe to use them both. We got additive amounts of proteinuria reduction, but there [were] some cross-signals in terms of the hyperkalemia.”
“with finerenone, what we see actually is that this is another trial, actually, in heart—in this population of individuals with HFpEF or HFmrEF—a population that’s historically been very difficult to treat and historically lacking in proven therapies. And this is really the second”
John Ostrominski · Fellow of Cardiovascular Medicine and Obesity Medicine · Pharmacy Times ↗
“Given that finerenone was beneficial in patients already receiving an SGLT2 inhibitor, our findings point to finerenone as a new second pillar in HFmrEF/HFpEF.”
Scott Solomon · Senior Physician and Director of Noninvasive Cardiology · TCTMD ↗
“Evidence increasingly suggests that combining SGLT2 inhibition and finerenone may provide additive benefits, but it has not been proven.”
“We had seen a meta-analysis beforehand by Brendon Neuen that showed that we would get less hyperkalemia when we combine finerenone plus SGLT2 inhibitors.”
Brendon Neuen · Nephrologist and clinical researcher · DocWire News ↗
Named experts we found publicly on record — a sample, not a representative poll of the field.
Who: HFpEF patients with T2D and CKD·9 sources
On the board:since Jun 22, 2026 (2 days)— time live on Synapse
Patients affected:Many patients· common overlap of HFpEF, diabetes, and kidney disease
›The evidence
What we know
✓Finerenone reduces cardiovascular and kidney events in diabetic kidney disease.
✓SGLT2 inhibitors already help HFpEF patients with diabetes and CKD.
✓The two drugs work through separate mechanisms, so additive benefit is biologically plausible.
✓Finerenone raises potassium, though SGLT2 inhibitors may partly offset this.
What's still unknown
?No dedicated trial tests the combination specifically in HFpEF.
?How much extra benefit finerenone adds once a patient is already on an SGLT2 inhibitor.
?Whether hyperkalemia stays manageable in routine, less-monitored practice.
?Whether the incremental benefit justifies the added cost.
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
“Timely cardiac MRI is really important in patients with MINOCA, because somewhere between 20 to 40 percent of patients may ultimately have a nonischemic diagnosis.”
“If CMRI were performed on all patients and the therapies were targeted to those patients with MINOCA with evidence of true myocardial infarction, perhaps the observed benefits would have been even greater.”
S. Pasupathy · Cardiologist/researcher · Circulation ↗
Undecided
“As cardiologists, we all see MINOCA patients, but we should now be moving on from just considering to actually providing these tests, especially vasospastic testing.”
“It’s maybe not very diplomatic, but it is a sort of laziness, because a lot of these technologies and test methods have been around for many, many years.”
“Masri responds by highlighting the MAPLE-HCM trial, in which aficamten, used as first-line monotherapy, outperformed metoprolol in terms of LVOT gradient reduction and symptomatic improvement.”
“As all completed phase 3 trials have included patients with high rates of background medical therapy, it is appropriate for beta-blockers and nondihydropyridine calcium channel blockers to remain first-line treatment for oHCM for the immediate future.”